Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 : vimarsana.com

Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO

Related Keywords

Oakland , California , United States , United Kingdom , University Of California San Francisco , Jerusalem , Israel General , Israel , San Francisco , American , Israeli , Ervin Epstein , Irina Koffler , Ervin Epstein Jr , Gilad Mamlok , Julie Breneiser , Nasdaq , National Institutes Of Health , Founder Of Pellepharm Inc , Company Annual Report On Form , Gorlin Syndrome Alliance , Hebrew University Of Jerusalem , Peptor Ltd , University Of California , Md Co , Exchange Commission , Pellepharm Inc , Society For Investigative Dermatology , Gel Technologies Ltd , American Dermatological Association , Research Dermatologist , Oxford University , Phd Co , Gel Technologies , Executive Director , Orphan Drug Designation , Breakthrough Designation , Chief Executive Officer , Sol Gel Therapeutics , Board President , Physician Assistant , National Institutes , Congressionally Directed Medical Research , Medical Advisor , Clinical Professor , American Dermatological , New England Journal , Alon Seri Levy , Hebrew University , Gorlin Syndrome , Orphan Drug , Private Securities Litigation Reform Act , Annual Report , Asal Cell Carcinomas , Orlin Syndrome , Rvin Epstein Jr , Rvin Epstein , Lon Seri Levy , Rphan Drug Designation , Ol Gel , Ermatology Products , Enetic Disorder , Hief Executive Officer ,